PwC declares biopharma ecosystem ‘back to full health’ as M&A buoys sector

Precision science is ruling the M&A scene as pharmas prepare for loss of exclusivity on key products, PwC says in a new report. Biotechs should be prepared with a dual-track process with the IPO window now open.